Search Within

David H Ilson

Formats
  1. Journal Article (209)
  2. Meeting Abstract (168)
  3. Book Section (20)
  4. Review (13)
  5. Editorial (9)
  6. Conference Paper (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Book Whole (1)
  10. Miscellaneous (1)
  11. Research Letter (1)
Groups
  1. Department of Medicine (433)
  2. Gastrointestinal Oncology Service (433)
  3. Solid Tumor Oncology Division (433)
  4. Center for Pancreatic Cancer Research (186)
  5. Surgery (136)
  6. Survivorship Research (127)

More Groups

People
  1. David Kelsen (132)
  2. Geoffrey Ku (122)
  3. Yelena Janjigian (111)
  4. Marinela Capanu (65)
  5. Laura Tang (60)
  6. Manjit Bains (51)

More People

Years
  1. 2025 (5)
  2. 2024 (16)
  3. 2023 (24)
  4. 2022 (21)
  5. 2021 (22)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (135)
  2. Annals of Oncology (28)
  3. International Journal of Radiation Oncology, Biology, Physics (15)
  4. Journal of the National Comprehensive Cancer Network (14)
  5. Annals of Surgical Oncology (13)
  6. Cancer (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (137)
  2. Elsevier Inc. (57)
  3. Oxford University Press (41)
  4. Springer (32)
  5. Lippincott Williams & Wilkins (22)
  6. Wiley Blackwell (18)

More Publishers

Results (433)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2-Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
    Meeting Abstract

    Xu, R. H.; Dongsheng, Z.; Ajani, J.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2(+)/HER2(-) locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shah, M.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shitara, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study
    Meeting Abstract

    Alsina, M.; Tabernero, J.; Arkenau, H. T.; Squadroni, M.; Doi, T.; Faustino, C.; Ghidini, M.; Mansoor, W.; Shitara, K.; Van Cutsem, E.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Van Cutsem, E.; Hochster, H. S.; Shitara, K.; Mayer, R. J.; Ohtsu, A.; Falcone, A.; Yoshino, T.; Doi, T.; Ilson, D. H.; Arkenau, H. T.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged >= 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS
    Meeting Abstract

    Shitara, K.; Doi, T.; Hosaka, H.; Thuss-Patience, P. C.; Santoro, A.; Jimenez-Fonseca, P.; Longo, F.; Ozyilkan, O.; Cicin, I.; Park, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS
    Meeting Abstract

    Mansoor, W.; Arkenau, H. T.; Alsina, M.; Shitara, K.; Tejani, M. A.; Thuss-Patience, P. C.; Cuffe, S.; Dvorkin, M.; Park, D.; Ando, T.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Greally, M.; Strong, V. E.; Yoon, S. S.; Coit, D. G.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Janjigian, Y. Y.; Ilson, D. H.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy
    Meeting Abstract

    Greally, M.; Walch, H. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Schultz, N.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save